47 results about "Human feces" patented technology

The invention relates to the technical field of microorganisms, in particular to application of pediococcus acidilactici. The pediococcus acidilactici TG005 is preserved in the China Center for Type Culture Collection on June 24, 2024, the preservation number is CCTCC NO: M 20241349, and the preservation address is Wuhan University, Wuhan, China. The pediococcus acidilactici TG005 provided by the invention is a multifunctional probiotic strain, is obtained by screening from domestic healthy human excrement samples, and has good application safety and functional adaptability; the strain can reduce the cholesterol level and prevent cardiovascular diseases; uric acid precursor substances are degraded, uric acid generation is reduced, and hyperuricemia and related diseases are prevented; pathogenic bacteria with fusobacterium nucleatum and bacteroides fragilis can be inhibited, and colorectal cancer is prevented; when being used as a probiotic additive for preparing medicines for degrading cholesterol, preventing cardiovascular diseases caused by high cholesterol, preventing hyperuricemia, colorectal cancer and the like, the lactobacillus plantarum has a wide application prospect.

The invention provides common bacteroides and application thereof. Specifically, a strain of common bacteroides capable of producing 3-indolepropionic acid is separated from human feces for the first time, and the strain of common bacteroides is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The strain of common bacteroides can be used for producing 3-indolepropionic acid, and the strain of common bacteroides can be used for producing 3-indolepropionic acid. Furthermore, the invention provides an application of the common bacteroides disclosed by the invention in production of 3-indolepropionic acid. Furthermore, the invention provides a method for producing the 3-indolepropionic acid by using the common bacteroides disclosed by the invention, and an application of the common bacteroides disclosed by the invention in increasing the content of the 3-indolepropionic acid in an organism.

The present invention discloses a Bifidobacterium breve strain capable of clearing toxins in the body and its postbiotics, belonging to the technical field of microbial applications. The present invention isolates a Bifidobacterium breve strain ( Bifidobacterium breve ) WZA-BB07 from human feces, and its biological deposit number is: CCTCC NO: M20241530. The strain WZA-BB07 has good effects in degrading endotoxin and enterotoxin. The strain and Lactobacillus mucosae are mixed and fermented to prepare postbiotics. Bifidobacterium breve mainly improves the balance of intestinal flora and inhibits the growth of harmful bacteria. Lactobacillus mucosae helps repair the intestinal barrier through its metabolites during fermentation, enhancing the metabolism and clearance of toxins; extracts of Dendrobium officinale, Lonicera japonica, and Pueraria lobata are added to the fermentation medium, which not only provides rich nutrition for fermentation but also exerts the antioxidant, anti-inflammatory, and intestinal repair-promoting effects of ingredients with both medicinal and edible properties, further enhancing the detoxification ability and overall health effects of the postbiotic product.

The invention provides a bifidobacterium longum subsp. Longum aFMT-103 strain, which is classified and named as Bifidobacterium longum subsp. Longum, is preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 65181. The invention also provides a preparation method of the bifidobacterium longum subsp. Longum aFMT-103 strain. The invention further provides a microbial preparation containing the aFMT-103 bacterial strain. In addition, the invention also provides an application of the strain or the microbial preparation in preparation of an anti-depression product, and also provides an anti-depression product. The bifidobacterium longum subsp. Longum aFMT-103 strain has the advantages that the bifidobacterium longum subsp. Longum aFMT-103 strain is separated from the faeces of healthy adults; the strain has a remarkable anti-depression effect, can be used for preparing a preparation for resisting depression symptoms, and is of great significance in prevention and adjuvant therapy of depression.

The invention relates to the technical field of biological medicine, and discloses bifidobacterium adolescentis YF-01 and application thereof in fermented milk. The bifidobacterium adolescentis YF-01 is separated from adult excrement and is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 20251308. Experiments prove that the bifidobacterium adolescentis YF-01 has good gastrointestinal fluid tolerance, the survival rate of the bifidobacterium adolescentis YF-01 can reach 90.1% after simulated gastric fluid treatment for 3 h, and the survival rate of the bifidobacterium adolescentis YF-01 can reach 72% after simulated intestinal fluid treatment for 4 h The strain has the self-aggregation rate of 88.83% and the hydrophobicity of 79.41%, has remarkable scavenging capacity on DPPH free radicals and hydroxyl free radicals, shows good antioxidant activity and adhesion capacity, and provides a theoretical basis for application of the strain in fermented milk. The strain and metabolites thereof can be used for preparing food, medicines or health care products capable of regulating intestinal flora and enhancing oxidation resistance, and have remarkable application potential in development of functional fermented milk products.

The invention provides a bifidobacterium longum subsp. Longum aFMT-102 strain, which is classified and named as Bifidobacterium longum subsp. Longum, is preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 65180. The invention also provides a preparation method of the bifidobacterium longum subsp. Longum aFMT-102 strain. The invention further provides a microbial preparation containing the aFMT-102 strain and application of the aFMT-102 strain and the microbial preparation in preparation of products for relieving intestinal tracts and relieving stress. Meanwhile, the invention also provides a product containing the strain aFMT-102 or a corresponding microbial preparation. The strain aFMT-102 is separated from excrement of healthy adults, has good acid resistance and bile salt resistance and relatively strong intestinal colonization ability, and has a remarkable effect in the aspects of relieving intestinal tracts and relieving pressure.

The invention discloses a strain of Bacteroides ovatus L2 and application of the strain of Bacteroides ovatus L2 in a product for preventing and treating vomitoxin toxicity. The strain is preserved in Guangdong Microbiological Culture Collection Center, the preservation number is GDMCC.No: 67205, and the preservation date is November 4, 2025. The strain is separated and purified from a healthy adult excrement sample, has the characteristics of good acid resistance, cholate resistance, gastrointestinal fluid resistance and the like, and is free of hemolysis and good in safety. The strain can effectively relieve the toxic effect induced by vomitoxin, mainly inhibits inflammatory factors and promotes expression of intestinal barrier functional proteins, can be applied to products of microecologics for preventing and treating DON toxicity, and has a good application prospect.

Disclosed herein are methods for administering a dose of a microbiota recovery therapy composition by colonoscopy. The methods disclosed herein are useful for the treatment of diseases and / or conditions of the digestive tract, such as Clostridium difficile infection (GDI), including recurrent GDI, and other gastrointestinal disorders. The method can result in improved quality of life. These methods are capable of altering the gut microbiota composition and / or the gut metabolome composition. The microbiota recovery therapy composition comprises a fecal microbiota suspension comprising: a fecal microorganism derived from a human fecal sample, and a solution of polyethylene glycol and brine.

The present disclosure provides freeze-dried and liquid compositions that include an extract of human feces. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's intestinal microbiota, and methods for treating a disease or condition such as hepatic encephalopathy.

The invention discloses a method for isolating and culturing Megasphaera elsdenii in the intestine and its application, belonging to the technical field of microbiology. The Megasphaera elsdenii (Megasphaera elsdenii) pSML provided by the invention was deposited at the Guangdong Provincial Microbial Culture Collection Center on October 19, 2022, and the deposit number is: GDMCC No: 62902. The method for isolating and culturing the Megasphaera elsdenii includes the following steps: S1 preparing a fecal suspension; S2 enrichment culture; S3 preparing a sample dilution; S4 strain screening; S5 isolation and purification culture; S6 in vitro fermentation. The invention uses human feces and performs enrichment culture before isolation and purification, which increases the proportion of the target bacteria in the screening process, reduces the isolation difficulty and improves the isolation efficiency. By using this bacterium for in vitro fermentation, it is found that it can utilize prebiotics to produce glutathione and has the potential to improve in vivo oxidative stress, providing new ideas for the future development and utilization of this bacterium.

The invention relates to the technical field of medicines, and discloses a bifidobacterium longum strain GZBAI 01 and application thereof in degradation of benzoic acid and prevention or treatment of colorectal cancer. The strain is separated from faeces of healthy people, genomics identification is carried out, the metabolic profile of the strain is measured through metabonomics, the strain can convert benzoic acid with carcinogenic risk into protocatechuic acid with antitumor activity through unique metabolic capability, meanwhile, the function of regulatory T cells (Treg) in tumor drainage lymph nodes can be inhibited, differentiation of CD8 + T cells is promoted, and the tumor drainage lymph nodes can be inhibited. Therefore, the colorectal cancer is prevented through double ways of eliminating cancerogen and generating therapeutic agents. A colorectal cancer mouse model and a subcutaneous tumor mouse model verify that the strain can significantly reduce the number and volume of tumors, and shows a benzoic acid conversion effect superior to that of other strains in vivo and in vitro, and a new way is provided for prevention and treatment of colorectal cancer.

The invention provides a directional sorting method of gram-positive bacteria, which comprises the following steps: S1, extracting a human excrement sample to obtain a human bacterium suspension; and S2, treating the human bacterium suspension by using an EDTA-2Na (Ethylene Diamine Tetraacetic Acid) solution and a NaCl solution at the same time. According to the method, the gram-negative bacteria in the intestinal flora can be effectively removed, and meanwhile, the activity of the gram-positive bacteria is kept as much as possible, so that the high-purity gram-positive bacteria flora is obtained.

The invention provides a simulated excrement sample for radioactive bioassay and application of the simulated excrement sample. The simulated excrement sample comprises inorganic components and organic components. The simulated excrement sample is close to real human excrement in composition, physicochemical properties and biological activity, nuclides are uniformly distributed in the simulated excrement sample and can be stored for a long time, and a reliable research tool can be provided for radioactive bioassay, especially in the fields of drug research and development, environmental monitoring and the like.

The present application belongs to the technical field of microbial inoculants, and particularly relates to a Phocaediola doleeri, and further discloses a use of the Phocaediola doleeri in preparing a product for preventing and treating glycolipid metabolic disorder. A YG0564 strain is screened from healthy adult feces, and is identified as the Phocaediola doleeri and classified and named as Phocaediola doleeri. The Phocaediola doleeri strain YG0564 contains cholesteryl sulfatase, and can significantly reduce blood fat and blood sugar in vivo and in vitro, and can obviously prevent and treat obesity and glycolipid metabolic disorder.

The invention provides a method for simultaneously determining the contents of various short-chain fatty acids in human excrement, and innovatively develops an artificial excrement simulated blank matrix and a related detection system in order to solve the industrial problem that an effective blank matrix is lacked in excrement short-chain fatty acid (SCFAs) detection. The blank matrix is composed of a diluent, a microbial structure simulation agent and a fiber matrix skeleton, the problem of natural matrix deficiency is solved, and high-throughput, standardized and accurate quantitative analysis of the SCFAs in the excrement is achieved. A calibration curve is constructed on the basis of the matrix, synchronous and accurate quantification of the SCFAs in the excrement including acetic acid, propionic acid, butyric acid and the like is realized by combining a 3-NPH / EDC-pyridine derivatization LC-MS / MS technology, the recovery rate of the method is as high as 92.6%-111.2%, and the matrix effect deviation is stabilized to be smaller than or equal to + / -5%. The matched kit integrates the blank matrix, an SCFAs standard substance, a butyric acid-d7 internal standard and a derivatization reagent, and provides a standardized detection process. According to the achievement, the accuracy (RSD is less than or equal to 5%) of excrement SCFAs detection is remarkably improved, and the technical blank in the field is effectively filled.

The invention relates to the technical field of microorganisms, and provides a Bifidobacterium pseudocatenatum aFMT-201, which is classified and named as Bifidobacterium pseudocatenatum, is preserved in Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No: 65182. The invention also provides a preparation method of the Bifidobacterium pseudocatenatum aFMT-201. The invention also provides a probiotic composition containing the bifidobacterium pseudominutus aFMT-201, and a preparation method of the probiotic composition containing the bifidobacterium pseudominutus aFMT-201. Meanwhile, the invention also provides an application of the bifidobacterium pseudominulatum aFMT-201 or the composition in preparation of a medicine for preventing or treating the metabolic syndrome, and provides a medicine for preventing / treating the metabolic syndrome. The bifidobacterium pseudomicrochain aFMT-201 strain is separated from faeces of healthy adults, and the strain has the effects of remarkably lowering lipid and improving insulin sensitivity and can play an effective role in improving metabolic syndromes.

The present invention concerns a Parabacteroides distasonis strain deposited under accession number CNCM I-5828. This strain can be useful in multiple applications, in particular incorporated in a nutritional supplement or in a composition for use as a medicament, especially in the prevention or treatment of visceral pain, preferably induced by Inflammatory Bowel Disease including Crohn's disease and Ulcerative Colitis, or by Irritable Bowel Syndrome.

The present disclosure provides freeze-dried compositions that include an extract of human feces and a flavoring agent, where the compositions, upon reconstitution with a liquid, have no objectionable odor and has no objectionable taste. Also provided are methods for making and using such compositions, including methods for replacing or supplementing or modifying a subject's colon microbiota, and methods for treating a disease. In some embodiments, the subject can be an individual with reduced ability to swallow, such as pill dysphagia, or an individual refractory to administration of a liquid having an objectionable odor or objectionable taste.

The invention discloses a detection kit for detecting calprotectin in human excrement, the detection kit is composed of a sample diluent and detection test paper, the detection test paper is composed of a bottom plate, a nitrocellulose membrane, a conjugate pad, a sample pad and absorbent paper, the absorbent paper, the nitrocellulose membrane, the conjugate pad and the sample pad are sequentially overlapped on the bottom plate, a shell is arranged outside the detection test paper, and the shell is connected with the sample pad. An observation window and a sample adding hole are formed in the shell, and the position of the observation window is matched with the position of the nitrocellulose membrane; the position of the sample adding hole is matched with the position of the sample pad; the nitrocellulose membrane is sequentially provided with a T1 detection line coated with an anti-calprotectin monoclonal antibody, a T2 detection line coated with an anti-calprotectin monoclonal antibody and a quality control line C coated with a goat anti-chicken IgY antibody and / or a goat anti-mouse IgG antibody; a calprotectin monoclonal antibody marked by colloidal gold is solidified on the combination pad, and the sample diluent is prepared from sodium chloride, EDTA (Ethylene Diamine Tetraacetic Acid), PEG (Polyethylene Glycol) 20000, Proclin-300 and purified water.

The invention provides a structural bacteria-based stone flora pharmaceutical composition. The structural bacteria-based stone flora pharmaceutical composition is prepared from live bacteria of bifidobacterium pseudominum aFMT-202, live bacteria of bifidobacterium longum subsp. Longum aFMT-104 and live bacteria of lactobacillus mucosa aFMT-501. The invention also provides a microbial medicinal preparation and a preparation method thereof, and also provides application of the composition in preparation of antidepressant drugs, intestinal anti-inflammatory drugs and antioxidant and anti-aging drugs. The three strains are separated from faeces of healthy adults, have acid resistance, bile salt resistance and intestinal epithelium adhesion capacity, can regulate neurotransmitter balance, enhance intestinal mucosal barrier and up-regulate endogenous antioxidant enzyme activity respectively, have complementary functions and are free of drug resistance and pathogenicity; the composition forms a composite preparation according to a specific ratio, can intervene in depression, chronic intestinal inflammation and aging-related functional decline, solves the limitation that the existing single-target medicine takes effect slowly, has large side effects and cannot intervene comprehensively, and overcomes the defect of clinical multi-target collaborative treatment.

The utility model relates to the technical field of human excrement treatment equipment, in particular to an exhaust device of a fermentation bin, which comprises a fermentation bin cover, the fermentation bin cover comprises an exhaust port, and the exhaust device further comprises an exhaust fan arranged in the exhaust port; the filter screen is arranged in the exhaust port and located on the air inlet side of the exhaust fan, so that waste impurities in the fermentation bin are prevented from directly entering the exhaust fan in the exhaust process, and the service life of the exhaust fan is effectively prolonged.

The invention relates to application of common bacteroides in reducing blood sugar. Specifically, the invention provides a common bacteroides J2525 with a hypoglycemic function, the bacteroides is a gram-negative bacterium separated and purified from human excrement, the bacteroides is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, the preservation number is CGMCC NO.46398, the preservation number is CGMCC NO.46398, the preservation number is CGMCC NO.46398, and the preservation number is CGMCC NO.46398. The invention further provides a preparation method of the bacteroides J2525. The invention further provides a preparation method of the bacteroides J2525. The invention further provides a preparation method of the bacteroides J2525 with the hypoglycemic function and application of the bacteroides J2525 with the hypoglycemic function. The invention also provides application of the common bacteroides J2525 in preparation of products for reducing blood sugar, improving glucose tolerance or improving insulin sensitivity. The invention shows that the common bacteroid strain J2525 can be developed as a probiotic with a good hypoglycemic effect, and has a high reference value for clinical application of the strain.

The invention provides a kit for detecting helicobacter pylori in a human excrement sample. The kit is used for detecting the helicobacter pylori in the human excrement sample. The kit is composed of three detection reagents: a) a detection reagent for specifically detecting the helicobacter pylori 23S RNA gene of a human excrement sample; b) a detection reagent for specifically detecting the helicobacter pylori UreB gene of the human excrement sample; and c) a detection reagent for specifically detecting the human endogenous reference gene beta-actin of the human excrement sample. The detection kit is composed of a helicobacter pylori 23S RNA gene, a helicobacter pylori UreB gene and a human endogenous reference gene beta-actin, and the unique UreB gene in the helicobacter pylori can make up the influence of homologous conserved sequence errors in the 23S RNA gene in a targeted manner; the complementary synergistic effect of the two can improve the detection accuracy of helicobacter pylori in human tissue samples such as human excrement, saliva and gastric mucosa, and helicobacter pylori infection can be diagnosed more effectively.

Methods and cartridges for detecting a target are provided. A biological sample is introduced into the cartridge. The target in the sample is photon labeled with fluorescent particles in a first liquid layer in a cartridge. Photon-labeled targets are separated from the sample into a second liquid layer within the cartridge, detected and counted to show the presence of the targets in the subject. The cartridge includes a containing reservoir, a mixing aperture for introducing the sample into the photonic marker and the magnetic particles, and an imaging aperture for detecting and counting targets from the sample. The sample may be a human fecal sample. A filter may be used to filter out particulates from the sample.

The invention discloses humanized lactobacillus johnsonii MYR-117 and application thereof, the preservation number of the humanized lactobacillus johnsonii MYR-117 is GDMCC No: 65346, the humanized lactobacillus johnsonii MYR-117 is separated and identified from a faeces sample of a healthy person, and a mouse myelosuppression model is further combined to find that the lactobacillus johnsonii can resist myelosuppression induced by cyclophosphamide, so that the lactobacillus johnsonii MYR-117 can be used for resisting myelosuppression induced by cyclophosphamide; the levels of white blood cells, hemoglobin, platelets and red blood cells can be increased, bone marrow cell apoptosis is reduced, the thighbone marrow form is recovered, and the bone marrow hematopoietic capacity is Therefore, the compound can be used for preparing anti-myelosuppression drugs, leukocyte increasing drugs, erythrocyte increasing drugs, chemotherapy adjuvant therapy drugs and health-care products. Meanwhile, as the lactobacillus johnsonii is edible probiotics, the lactobacillus johnsonii can be used for preparing health-care food.

The invention relates to an environment-friendly ball type toilet which comprises a base unit, a liquid basin unit, an improved two-liquid flow divider, a solid excrement receiving unit, an excrement ball preparation chamber unit, a pressure sensor, a control unit and an execution unit. The liquid basin unit and the improved two-liquid diverter jointly form a liquid treatment device of the toilet, human urine falls into the urine funnel after being diverted by the two-liquid diverter and then flows into the urine output pipe, and washing liquid for flushing the basin body falls into the washing liquid funnel after being diverted by the two-liquid diverter and then flows into the washing liquid output pipe. Urine output by the urine output pipe is pure, and washing liquid output by the washing liquid output pipe contains a small amount of urine, so that the purpose of collecting the urine of people is achieved, and as the domestic sewage contains a small amount of human urine, the urban and rural environmental protection pressure is greatly relieved, and the water ecological environment of the earth is effectively protected; under the action of an electric signal of the execution unit, the main motor drives the excrement ball preparation chamber unit to rotate in a single direction, solid excrement of people and auxiliary materials are mixed, collided, rubbed and extruded, the excrement is divided into small block masses from large block masses, the surfaces of the small block masses are solidified, then excrement balls are prepared, and finally the main motor drives the excrement ball preparation chamber unit to rotate in the same direction. The excrement balls are conveyed into the excrement guide pipe and can be conveniently output to an external pipeline, and the purpose of collecting solid excrement of people is achieved.

The present application relates to a kind of Bacteroides in lowering blood sugar. Specifically, the present application provides a kind of Bacteroides plebeius J2525 with the function of lowering blood sugar, which is a strain of gram-negative bacteria isolated and purified from human feces, which has been preserved in China General Microbiological Culture Collection Center (CGMCC) on April 25, 2025, and the preservation number is CGMCC NO.46398. The present application also provides the use of Bacteroides plebeius J2525 of the present application in the preparation of products for lowering blood sugar, improving glucose tolerance or improving insulin sensitivity. The present application shows that Bacteroides plebeius strain J2525 can be developed as a kind of probiotics with good blood sugar lowering effect, and has high reference value for the application of the strain in clinic.

The application discloses an intestinal flora regulator containing unsaturated oligogalacturonic acid and application thereof, and an effective component of the intestinal flora regulator containing unsaturated oligogalacturonic acid comprises lemon unsaturated oligogalacturonic acid with a molecular weight of 80-85 kDa and an unsaturation degree of 7-10. The application finds that the intestinal flora regulator containing unsaturated oligogalacturonic acid has a regulating effect on intestinal flora by simulating an in-vivo environment in vitro and collecting intestinal microorganisms in human feces, including regulating the abundance, structure and diversity of intestinal flora, promoting the proliferation of beneficial bacteria such as bifidobacterium and lactobacillus, and inhibiting the proliferation of escherichia shigella and bacteroides, and can provide help for the development of intestinal disease treatment drugs.

The invention discloses a lactobacillus casei strain capable of warming uterus, dispelling cold and improving breast health and a metagen thereof, and belongs to the technical field of microbial application, the lactobacillus casei strain WZA-LC26 is separated from human excrement, and the biological preservation number of the lactobacillus casei strain is CCTCC (China Center for Type Culture Collection) NO: M20241410. According to the invention, the lactobacillus casei capable of warming uterus, dispelling cold and improving breast health is screened out, aftergrowth elements and medicinal and edible substances are combined, a natural and efficient health conditioning scheme capable of treating both symptoms and root causes is created, and through the combination, the effects of warming channels, dispelling cold, promoting blood circulation, removing blood stasis, soothing liver-qi stagnation and the like of traditional Chinese medicines can be fully utilized, so that the effects of warming uterus, dispelling cold, promoting blood circulation, removing blood stasis, soothing liver-qi stagnation and the like are achieved; the curative effect and the safety of the medicine can be remarkably improved by virtue of the multi-target effects of immunoregulation, anti-inflammation and anti-oxidation, endocrine balance promotion and the like of the metaplasts.

The invention discloses a mobile odor-free toilet, comprising a toilet cover, the toilet cover is connected with a toilet seat pad through a rotating shaft, and the toilet seat pad is fixed to a base through a connecting plate. Compared with the prior art, the advantages of the present invention are: it can change the sanitary environment pollution when used in rural areas, no feces storage tank is needed, groundwater resources are not polluted, mosquitoes and flies gather and do not spread diseases, it can be used outdoors in summer and indoors in winter, and feces are centrally processed; it is suitable for use in all non-fixed places such as RVs, mobile toilets, elderly women and children at home or patients with mobility difficulties, hospital wards, etc., reducing the labor intensity of management personnel, providing a safer, cleaner and more practical toilet environment, avoiding the waste of water resources, and can be used indoors and outdoors, without a feces storage tank, feces do not fall to the ground, human feces do not meet, no water flushing is needed, and it is cleaned every few days, the cost is low, and feces are used for agricultural production after centralized fermentation treatment, which can drive other industries.